Inhibikase Therapeutics Inc. (IKT)
NASDAQ · Healthcare
Inhibikase Therapeutics Inc. Revenue 2020–2024
Inhibikase Therapeutics Inc. annual/quarterly revenue history and growth rate from 2020 to 2026. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Inhibikase Therapeutics Inc. revenue for the quarter ending March 31, 2026 was 0.
- Inhibikase Therapeutics Inc. revenue for the twelve months ending March 31, 2026 was 0, a 100.00% decrease year-over-year.
- Inhibikase Therapeutics Inc. annual revenue for 2024 was 0, a 100.00% decrease from 2023.
- Inhibikase Therapeutics Inc. annual revenue for 2023 was 260501, a 111.03% increase from 2022.
- Inhibikase Therapeutics Inc. annual revenue for 2022 was 123440, a 96.02% decrease from 2021.
- Inhibikase Therapeutics Inc. annual revenue for 2021 was 3.1 M.
Revenue
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Inhibikase Therapeutics Inc. Earnings — FAQ
Inhibikase Therapeutics Inc. (IKT) earnings over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see IKT's earnings history?
The chart and table above show Inhibikase Therapeutics Inc.'s earnings by year and by quarter, including the growth rate.